List of Tables
Table 1. Global Tubulin Inhibitors for Breast Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Eribulin
Table 3. Key Players of Ixabepilone
Table 4. Key Players of Docetaxel
Table 5. Key Players of Trastuzumab Emtansine
Table 6. Key Players of Utidelone
Table 7. Key Players of Paclitaxel
Table 8. Key Players of Liposome Paclitaxel
Table 9. Global Tubulin Inhibitors for Breast Cancer Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Tubulin Inhibitors for Breast Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Tubulin Inhibitors for Breast Cancer Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Tubulin Inhibitors for Breast Cancer Market Share by Region (2020-2025)
Table 13. Global Tubulin Inhibitors for Breast Cancer Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Tubulin Inhibitors for Breast Cancer Market Share by Region (2026-2031)
Table 15. Tubulin Inhibitors for Breast Cancer Market Trends
Table 16. Tubulin Inhibitors for Breast Cancer Market Drivers
Table 17. Tubulin Inhibitors for Breast Cancer Market Challenges
Table 18. Tubulin Inhibitors for Breast Cancer Market Restraints
Table 19. Global Tubulin Inhibitors for Breast Cancer Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Tubulin Inhibitors for Breast Cancer Market Share by Players (2020-2025)
Table 21. Global Top Tubulin Inhibitors for Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tubulin Inhibitors for Breast Cancer as of 2024)
Table 22. Ranking of Global Top Tubulin Inhibitors for Breast Cancer Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Tubulin Inhibitors for Breast Cancer Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Tubulin Inhibitors for Breast Cancer, Headquarters and Area Served
Table 25. Global Key Players of Tubulin Inhibitors for Breast Cancer, Product and Application
Table 26. Global Key Players of Tubulin Inhibitors for Breast Cancer, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Tubulin Inhibitors for Breast Cancer Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Tubulin Inhibitors for Breast Cancer Revenue Market Share by Type (2020-2025)
Table 30. Global Tubulin Inhibitors for Breast Cancer Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Tubulin Inhibitors for Breast Cancer Revenue Market Share by Type (2026-2031)
Table 32. Global Tubulin Inhibitors for Breast Cancer Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Tubulin Inhibitors for Breast Cancer Revenue Market Share by Application (2020-2025)
Table 34. Global Tubulin Inhibitors for Breast Cancer Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Tubulin Inhibitors for Breast Cancer Revenue Market Share by Application (2026-2031)
Table 36. North America Tubulin Inhibitors for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Tubulin Inhibitors for Breast Cancer Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Tubulin Inhibitors for Breast Cancer Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Tubulin Inhibitors for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Tubulin Inhibitors for Breast Cancer Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Tubulin Inhibitors for Breast Cancer Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Tubulin Inhibitors for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Tubulin Inhibitors for Breast Cancer Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Tubulin Inhibitors for Breast Cancer Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Tubulin Inhibitors for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Tubulin Inhibitors for Breast Cancer Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Tubulin Inhibitors for Breast Cancer Market Size by Country (2026-2031) & (US$ Million)
Table 51. Eisai Company Details
Table 52. Eisai Business Overview
Table 53. Eisai Tubulin Inhibitors for Breast Cancer Product
Table 54. Eisai Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 55. Eisai Recent Development
Table 56. Bristol-Myers Squibb Company Details
Table 57. Bristol-Myers Squibb Business Overview
Table 58. Bristol-Myers Squibb Tubulin Inhibitors for Breast Cancer Product
Table 59. Bristol-Myers Squibb Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 60. Bristol-Myers Squibb Recent Development
Table 61. Otsuka Pharmaceutical Company Details
Table 62. Otsuka Pharmaceutical Business Overview
Table 63. Otsuka Pharmaceutical Tubulin Inhibitors for Breast Cancer Product
Table 64. Otsuka Pharmaceutical Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 65. Otsuka Pharmaceutical Recent Development
Table 66. Hengrui Medicine Company Details
Table 67. Hengrui Medicine Business Overview
Table 68. Hengrui Medicine Tubulin Inhibitors for Breast Cancer Product
Table 69. Hengrui Medicine Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 70. Hengrui Medicine Recent Development
Table 71. Sanofi Company Details
Table 72. Sanofi Business Overview
Table 73. Sanofi Tubulin Inhibitors for Breast Cancer Product
Table 74. Sanofi Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 75. Sanofi Recent Development
Table 76. Qilu Pharma Company Details
Table 77. Qilu Pharma Business Overview
Table 78. Qilu Pharma Tubulin Inhibitors for Breast Cancer Product
Table 79. Qilu Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 80. Qilu Pharma Recent Development
Table 81. Shenzhen Main Luck Pharma Company Details
Table 82. Shenzhen Main Luck Pharma Business Overview
Table 83. Shenzhen Main Luck Pharma Tubulin Inhibitors for Breast Cancer Product
Table 84. Shenzhen Main Luck Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 85. Shenzhen Main Luck Pharma Recent Development
Table 86. Jiangsu Aosaikang Pharma Company Details
Table 87. Jiangsu Aosaikang Pharma Business Overview
Table 88. Jiangsu Aosaikang Pharma Tubulin Inhibitors for Breast Cancer Product
Table 89. Jiangsu Aosaikang Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 90. Jiangsu Aosaikang Pharma Recent Development
Table 91. Genentech Company Details
Table 92. Genentech Business Overview
Table 93. Genentech Tubulin Inhibitors for Breast Cancer Product
Table 94. Genentech Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 95. Genentech Recent Development
Table 96. Beijing Biostar Technologies Company Details
Table 97. Beijing Biostar Technologies Business Overview
Table 98. Beijing Biostar Technologies Tubulin Inhibitors for Breast Cancer Product
Table 99. Beijing Biostar Technologies Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 100. Beijing Biostar Technologies Recent Development
Table 101. Celgene Corporation Company Details
Table 102. Celgene Corporation Business Overview
Table 103. Celgene Corporation Tubulin Inhibitors for Breast Cancer Product
Table 104. Celgene Corporation Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 105. Celgene Corporation Recent Development
Table 106. Hospira Company Details
Table 107. Hospira Business Overview
Table 108. Hospira Tubulin Inhibitors for Breast Cancer Product
Table 109. Hospira Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 110. Hospira Recent Development
Table 111. Biological E. Company Details
Table 112. Biological E. Business Overview
Table 113. Biological E. Tubulin Inhibitors for Breast Cancer Product
Table 114. Biological E. Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 115. Biological E. Recent Development
Table 116. Taj Accura Company Details
Table 117. Taj Accura Business Overview
Table 118. Taj Accura Tubulin Inhibitors for Breast Cancer Product
Table 119. Taj Accura Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 120. Taj Accura Recent Development
Table 121. Khandelwal Laboratories Company Details
Table 122. Khandelwal Laboratories Business Overview
Table 123. Khandelwal Laboratories Tubulin Inhibitors for Breast Cancer Product
Table 124. Khandelwal Laboratories Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 125. Khandelwal Laboratories Recent Development
Table 126. Luye Pharma Company Details
Table 127. Luye Pharma Business Overview
Table 128. Luye Pharma Tubulin Inhibitors for Breast Cancer Product
Table 129. Luye Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 130. Luye Pharma Recent Development
Table 131. Beijing Youcare Company Details
Table 132. Beijing Youcare Business Overview
Table 133. Beijing Youcare Tubulin Inhibitors for Breast Cancer Product
Table 134. Beijing Youcare Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 135. Beijing Youcare Recent Development
Table 136. Beijing Union Company Details
Table 137. Beijing Union Business Overview
Table 138. Beijing Union Tubulin Inhibitors for Breast Cancer Product
Table 139. Beijing Union Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 140. Beijing Union Recent Development
Table 141. Haiyao Company Details
Table 142. Haiyao Business Overview
Table 143. Haiyao Tubulin Inhibitors for Breast Cancer Product
Table 144. Haiyao Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 145. Haiyao Recent Development
Table 146. Chuntch Company Details
Table 147. Chuntch Business Overview
Table 148. Chuntch Tubulin Inhibitors for Breast Cancer Product
Table 149. Chuntch Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 150. Chuntch Recent Development
Table 151. CSPC Pharmaceutical Company Details
Table 152. CSPC Pharmaceutical Business Overview
Table 153. CSPC Pharmaceutical Tubulin Inhibitors for Breast Cancer Product
Table 154. CSPC Pharmaceutical Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 155. CSPC Pharmaceutical Recent Development
Table 156. Aosaikang Pharm Company Details
Table 157. Aosaikang Pharm Business Overview
Table 158. Aosaikang Pharm Tubulin Inhibitors for Breast Cancer Product
Table 159. Aosaikang Pharm Revenue in Tubulin Inhibitors for Breast Cancer Business (2020-2025) & (US$ Million)
Table 160. Aosaikang Pharm Recent Development
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
Table 164. Authors List of This Report
List of Figures
Figure 1. Tubulin Inhibitors for Breast Cancer Picture
Figure 2. Global Tubulin Inhibitors for Breast Cancer Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Tubulin Inhibitors for Breast Cancer Market Share by Type: 2024 VS 2031
Figure 4. Eribulin Features
Figure 5. Ixabepilone Features
Figure 6. Docetaxel Features
Figure 7. Trastuzumab Emtansine Features
Figure 8. Utidelone Features
Figure 9. Paclitaxel Features
Figure 10. Liposome Paclitaxel Features
Figure 11. Protein-bound Paclitaxel Features
Figure 12. Global Tubulin Inhibitors for Breast Cancer Market Size by Application (2020-2031) & (US$ Million)
Figure 13. Global Tubulin Inhibitors for Breast Cancer Market Share by Application: 2024 VS 2031
Figure 14. Hospital Case Studies
Figure 15. Clinic Case Studies
Figure 16. Drug Center Case Studies
Figure 17. Others Case Studies
Figure 18. Tubulin Inhibitors for Breast Cancer Report Years Considered
Figure 19. Global Tubulin Inhibitors for Breast Cancer Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 20. Global Tubulin Inhibitors for Breast Cancer Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 21. Global Tubulin Inhibitors for Breast Cancer Market Share by Region: 2024 VS 2031
Figure 22. Global Tubulin Inhibitors for Breast Cancer Market Share by Players in 2024
Figure 23. Global Top Tubulin Inhibitors for Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tubulin Inhibitors for Breast Cancer as of 2024)
Figure 24. The Top 10 and 5 Players Market Share by Tubulin Inhibitors for Breast Cancer Revenue in 2024
Figure 25. North America Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. North America Tubulin Inhibitors for Breast Cancer Market Share by Country (2020-2031)
Figure 27. United States Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Canada Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Europe Tubulin Inhibitors for Breast Cancer Market Share by Country (2020-2031)
Figure 31. Germany Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. France Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. U.K. Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Italy Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Russia Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Nordic Countries Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Tubulin Inhibitors for Breast Cancer Market Share by Region (2020-2031)
Figure 39. China Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Japan Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. South Korea Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. India Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Australia Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Latin America Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Latin America Tubulin Inhibitors for Breast Cancer Market Share by Country (2020-2031)
Figure 47. Mexico Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Brazil Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Middle East & Africa Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Middle East & Africa Tubulin Inhibitors for Breast Cancer Market Share by Country (2020-2031)
Figure 51. Turkey Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. UAE Tubulin Inhibitors for Breast Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Eisai Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 55. Bristol-Myers Squibb Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 56. Otsuka Pharmaceutical Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 57. Hengrui Medicine Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 58. Sanofi Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 59. Qilu Pharma Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 60. Shenzhen Main Luck Pharma Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 61. Jiangsu Aosaikang Pharma Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 62. Genentech Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 63. Beijing Biostar Technologies Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 64. Celgene Corporation Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 65. Hospira Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 66. Biological E. Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 67. Taj Accura Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 68. Khandelwal Laboratories Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 69. Luye Pharma Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 70. Beijing Youcare Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 71. Beijing Union Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 72. Haiyao Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 73. Chuntch Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 74. CSPC Pharmaceutical Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 75. Aosaikang Pharm Revenue Growth Rate in Tubulin Inhibitors for Breast Cancer Business (2020-2025)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
